The American Journal of Surgery
Volume 198, Issue 6 , Pages 781-786 , December 2009

A novel intralymphatic nanocarrier delivery system for cisplatin therapy in breast cancer with improved tumor efficacy and lower systemic toxicity in vivo

  • Mark S. Cohen, M.D., F.A.C.S.

      Affiliations

    • Department of Surgery, University of Kansas, Medical Center, Kansas City, KS, United States
    • SC and MSC are co-first authors.
    • ,
  • Shuang Cai, M.S.

      Affiliations

    • Department of Pharmaceutical Chemistry, 2095 Constant Ave., University of Kansas, Lawrence, KS 66047, United States
    • SC and MSC are co-first authors.
    • ,
  • Yumei Xie, Ph.D.

      Affiliations

    • Department of Pharmaceutical Chemistry, 2095 Constant Ave., University of Kansas, Lawrence, KS 66047, United States
    • ,
  • M. Laird Forrest, Ph.D.

      Affiliations

    • Department of Pharmaceutical Chemistry, 2095 Constant Ave., University of Kansas, Lawrence, KS 66047, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1-785-864-4388; fax: +1-785-864-5736

Received 5 March 2009 ,Revised 2 June 2009

References 

  1. American Cancer Society. Facts Figures 2007.
  2. Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995;332:901–906
  3. Hassett MJ, O'Malley AJ, Pakes JR, et al. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst. 2006;98:1108–1117
  4. Hartmann JT, Kollmannsberger C, Kanz L, et al. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer. 1999;83:866–869
  5. Zuur CL, Simis YJ, Verkaik RS, et al. Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer. Radiother Oncol. 2008;89:38–43
  6. Shimizu Y, Hasumi K. Chemotherapy with consecutive low-dose CDDP combined with 5-FU for gynecologic malignancies. Gan To Kagaku Ryoho. 1999;26:1564–1574
  7. Sanki A, Kam PC, Thompson JF. Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology. Ann Surg. 2007;245:591–596
  8. Noda T, Ohigashi H, Ishikawa O, et al. Liver perfusion chemotherapy for selected patients at a high-risk of liver metastasis after resection of duodenal and ampullary cancers. Ann Surg. 2007;246:799–805
  9. Cai S, Xie Y, Bagby TR, et al. Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate. J Surg Res. 2008;147:247–252
  10. Vantyghem SA, Allan AL, Postenka CO, et al. A new model for lymphatic metastasis: development of a variant of the MDA-MB-468 human breast cancer cell line that aggressively metastasizes to lymph nodes. Clin Exp Metastasis. 2005;22:351–361
  11. Maeda M, Takasuka N, Suga T, et al. Antitumor activity of a new series of platinum complexes: trans(+/−)−1,2-cyclohexanediammineplatinum(II) conjugated to acid polysaccharides. Anticancer Drugs. 1993;4:167–171
  12. National Cancer Institute. Breast cancer PDQ Treatment. 2007 http://www.cancer.gov/cancertopics/pdq/treatment/breast/HealthProfessional
  13. Armer JM. The problem of post-breast cancer lymphedema: impact and measurement issues. Cancer Invest. 2005;1:76–83
  14. Cochran AJ, Roberts AA, Saida T. The place of lymphatic mapping and sentinel node biopsy in oncology. Int J Clin Oncol. 2003;8:139–150
  15. Chen JH, Ling R, Yao Q, et al. Effect of small-sized liposomal Adriamycin administered by various routes on a metastatic breast cancer model. Endocr Relat Cancer. 2005;12:93–100
  16. Sirohi B, Arnedos M, Popat S, et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol. 2008;19:1847–1852
  17. Rhiem K, Wappenschmidt B, Bosse K, et al. Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer. Clin Oncol (R Coll Radiol). 2009;21:448–450
  18. Byrski T, Huzarski T, Dent R, et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2008;115:359–363

 Supported in part by grants from NIH (R21 CA132033-01, P20 RR015563) and the American Cancer Society (RSG-08-133-01-CDD).

PII: S0002-9610(09)00554-6

doi: 10.1016/j.amjsurg.2009.07.032

The American Journal of Surgery
Volume 198, Issue 6 , Pages 781-786 , December 2009

Article Tools

* Image Usage & Resolution